Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing diagnostic criteria in Waldenstrom's macroglobulinemia.

Roger G Owen1

  • 1HMDS Laboratory, The General Infirmary at Leeds, Leeds, UK.

Seminars in Oncology
|April 30, 2003
PubMed
Summary

Waldenstrom's macroglobulinemia (WM) diagnosis requires standardized criteria. This study proposes new criteria including IgM monoclonal gammopathy, bone marrow infiltration, and specific immunophenotypes for better clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Blood advances·2026
Same author

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

Blood advances·2025
Same author

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Blood·2025
Same author

Report of Consensus Panel 4 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma.

Seminars in hematology·2025
Same author

Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia.

Seminars in hematology·2025
Same author

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenstrom's macroglobulinemia (WM) is an understudied B-cell lymphoproliferative disorder.
  • Limited clinicopathological data and non-randomized trials hinder progress.
  • Lack of universally accepted diagnostic criteria impedes research and treatment.

Purpose of the Study:

  • To establish universally accepted diagnostic criteria for Waldenstrom's macroglobulinemia.
  • To facilitate future standardized clinical trials for WM.
  • To improve the characterization and understanding of WM.

Main Methods:

  • Clinicopathological assessment of 111 patients.
  • Comprehensive review of published literature on WM.
  • Proposal of integrated diagnostic criteria.

Related Experiment Videos

Main Results:

  • Proposed WM diagnostic criteria include: IgM monoclonal gammopathy, specific bone marrow infiltration patterns (small lymphocytes, plasmacytoid cells, plasma cells), and a defined immunophenotype (Ig+, CD19+, CD20+, CD5-, CD10-, CD23-).
  • These criteria integrate clinical, morphological, immunophenotypic, and genotypic parameters.

Conclusions:

  • The proposed criteria provide a foundation for standardized WM diagnosis.
  • Implementation of these criteria will enhance the quality and comparability of future clinical trials.
  • Standardized diagnosis is crucial for advancing WM research and patient care.